Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stake Lifted by Noked Israel Ltd

Noked Israel Ltd grew its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 14.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,285,359 shares of the company’s stock after acquiring an additional 418,006 shares during the period. Teva Pharmaceutical Industries comprises 14.3% of Noked Israel Ltd’s investment portfolio, making the stock its 3rd biggest position. Noked Israel Ltd’s holdings in Teva Pharmaceutical Industries were worth $72,409,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company’s stock worth $1,806,910,000 after acquiring an additional 19,242,468 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its stake in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock valued at $859,935,000 after acquiring an additional 4,418,961 shares in the last quarter. Ion Asset Management Ltd. increased its holdings in Teva Pharmaceutical Industries by 1.1% during the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company’s stock worth $807,766,000 after acquiring an additional 409,778 shares during the period. Lingotto Investment Management LLP increased its holdings in shares of Teva Pharmaceutical Industries by 2.6% in the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock worth $599,320,000 after purchasing an additional 688,862 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. raised its stake in Teva Pharmaceutical Industries by 2.2% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock valued at $573,822,000 after purchasing an additional 569,412 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA opened at $17.48 on Wednesday. The firm has a market capitalization of $19.82 billion, a P/E ratio of -12.06, a PEG ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The business has a fifty day moving average of $15.22 and a 200 day moving average of $17.44. Teva Pharmaceutical Industries Limited has a one year low of $12.47 and a one year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.48 EPS. As a group, sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TEVA. UBS Group cut their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Bank of America boosted their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Wednesday, April 23rd. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a report on Monday, April 28th. Finally, JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $21.00 to $23.00 in a research note on Monday. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries has an average rating of “Buy” and an average target price of $24.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.